Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership

Tilray Advances UK Healthcare Platform with Lyphe Acquisition, Positions BrewDog for Strong Growth, and Prepares for U.S. Rescheduling and Medical Cannabis Opportunity

Apr. 15, 2026 at 12:05pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished glass bottle, a sleek metal canister, and a stack of premium-looking paperwork, all arranged elegantly on a clean, monochromatic background, conceptually representing Tilray Brands' corporate strategy and global expansion.Tilray Brands' strategic investments in healthcare, cannabis, and craft beverages position the company for global growth and market leadership.NYC Today

Tilray Brands, Inc., a global lifestyle and consumer packaged goods company, announced a series of strategic initiatives marking its next phase of global growth, expanding its leadership across healthcare, cannabis and beverage while strengthening its ability to expand internationally and capture emerging market opportunities.

Why it matters

This move by Tilray Brands positions the company to capitalize on the growing global demand for medical cannabis, craft beverages, and other wellness products as it continues to diversify its portfolio and strengthen its global footprint.

The details

Tilray acquired the Lyphe Group, a leading UK-based medical cannabis clinic and digital pharmacy platform, to expand its vertically integrated medical ecosystem in Europe. The company also plans to accelerate the growth of its BrewDog craft beer brand by investing in the brand, innovation pipeline, and brewpub experience. Additionally, Tilray is preparing for the potential rescheduling of medical cannabis in the U.S. and is evaluating opportunities to participate in the Center for Medicare and Medicaid Innovation pilot program.

  • Tilray acquired the Lyphe Group in April 2026.
  • Tilray plans to launch Hi*Ball Energy in the UK in May 2026.
  • Tilray expects the BrewDog business to be cash flow positive in 2027.

The players

Irwin D. Simon

Chairman and Chief Executive Officer of Tilray Brands.

Rajnish Ohri

President, International, Tilray Brands.

Denise Faltischek

Chief Strategy Officer and Head of M&A, Tilray Brands.

Carl Merton

Chief Financial Officer, Tilray Brands.

Lyphe Group

A leading UK-based medical cannabis clinic and digital pharmacy platform acquired by Tilray.

Got photos? Submit your photos here. ›

What they’re saying

“Tilray Brands is setting the pace for global innovation across healthcare, cannabis, and craft beverages - each a distinct growth engine within our platform. This is a defining moment as we enter our next phase of global growth.”

— Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands

“I'm proud to welcome the Lyphe team to Tilray, bringing deep clinical expertise and a strong patient-first approach that immediately strengthens our capabilities. This acquisition marks an important step in the continued expansion of Tilray Medical as a global healthcare platform.”

— Rajnish Ohri, President, International, Tilray Brands

“Our priorities are clear: strengthen BrewDog, accelerate innovation, and scale our global beverage platform. We are already taking decisive steps to reinvest in the BrewDog brand, innovation pipeline, and brewpub experience, and we see a clear path to rebuilding BrewDog toward its prior valuation of over $1 billion.”

— Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands

“Upon rescheduling, Tilray Medical is strategically positioned to participate in a U.S. regulated medical cannabis market, evidenced by our proven track record of operating at scale in highly-regulated medical cannabis markets globally, supported by our pharmaceutical quality systems, scientific expertise, and our ongoing commitment to education and clinical research.”

— Denise Faltischek, Chief Strategy Officer and Head of M&A, Tilray Brands

“We remain focused on disciplined capital allocation, prioritizing investments that support our long-term growth strategy while maintaining a strong balance sheet. This structure allows us to align capital deployment with evolving market conditions and our operational priorities.”

— Carl Merton, Chief Financial Officer, Tilray Brands

What’s next

Tilray is closely monitoring the rescheduling of medical cannabis in the United States and is actively engaged with legislators and regulators as they evaluate and work towards this important evolution in drug policy.

The takeaway

Tilray Brands is positioning itself as a global leader in the healthcare, cannabis, and beverage industries through strategic acquisitions, investments, and preparations for emerging market opportunities. The company's diversified portfolio and focus on innovation and growth are expected to drive long-term success.